Last reviewed · How we verify

Statin plus fenofibrate — Competitive Intelligence Brief

Statin plus fenofibrate (Statin plus fenofibrate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination lipid-lowering agent (statin + fibrate). Area: Cardiovascular.

marketed Combination lipid-lowering agent (statin + fibrate) HMG-CoA reductase (statin component); PPAR-alpha (fenofibrate component) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Statin plus fenofibrate (Statin plus fenofibrate) — University of Ioannina. This combination reduces cholesterol and triglycerides through dual lipid-lowering pathways: statins inhibit HMG-CoA reductase to lower LDL cholesterol, while fenofibrate activates PPAR-alpha to reduce triglycerides and raise HDL cholesterol.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Statin plus fenofibrate TARGET Statin plus fenofibrate University of Ioannina marketed Combination lipid-lowering agent (statin + fibrate) HMG-CoA reductase (statin component); PPAR-alpha (fenofibrate component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination lipid-lowering agent (statin + fibrate) class)

  1. University of Ioannina · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Statin plus fenofibrate — Competitive Intelligence Brief. https://druglandscape.com/ci/statin-plus-fenofibrate. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: